

# Halis K Akturk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9344817/publications.pdf>

Version: 2024-02-01

75  
papers

1,578  
citations

257450

24  
h-index

345221

36  
g-index

79  
all docs

79  
docs citations

79  
times ranked

1761  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 84-92.	4.4	42
2	Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 677-682.	2.2	14
3	Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. <i>Diabetes Care</i> , 2022, 45, 750-753.	8.6	31
4	Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 373-380.	4.4	43
5	Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 481-483.	8.6	4
6	Diabetes Technology Meeting 2021. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210902.	2.2	2
7	Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 749-753.	4.4	10
8	Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 779-783.	4.4	20
9	Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 81-83.	4.4	7
10	The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 960-968.	8.6	21
11	Locating Hormone-Releasing Contraceptive Implants Using Near-Infrared Light. <i>Obstetrics and Gynecology</i> , 2021, 137, 443-444.	2.4	1
12	Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-21-S-26.	4.4	39
13	Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards. <i>Diabetes Care</i> , 2021, 44, e121-e123.	8.6	40
14	Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2048-2057.	4.4	28
15	A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1936-1941.	4.4	2
16	715-P: A Randomized, Controlled Trial of Transition from Insulin Pump to Multiple Daily Injections Using Insulin Degludec. <i>Diabetes</i> , 2021, 70, .	0.6	0
17	149-OR: Evaluation of the Next Generation 180-Day Long-Term Implantable Eversense CGM System: PROMISE Study. <i>Diabetes</i> , 2021, 70, .	0.6	3
18	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1630-1640.	8.6	133

#	ARTICLE	IF	CITATIONS
19	236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Diabetes</i> , 2021, 70, .	0.6	1
20	Gastric Emptying Abnormalities in Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2021, 385, 575-576.	27.0	2
21	Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108030.	2.3	5
22	Comparison of cgmanalysis, a free, open-source continuous glucose monitoring (CGM) data management and analysis software to commercially available CGM platforms: Data standardization for diabetes technology research. <i>Diabetes Technology and Therapeutics</i> , 2021, , .	4.4	5
23	Pivotal Evaluation of an Artificial Intelligence System for Autonomous Detection of Referrable and Vision-Threatening Diabetic Retinopathy. <i>JAMA Network Open</i> , 2021, 4, e2134254.	5.9	83
24	Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Findings From the T1D Exchange Clinic Registry. <i>Diabetes Care</i> , 2020, 43, 247-249.	8.6	28
25	Suicide and Self-inflicted Injury in Diabetes: A Balancing Act. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 1010-1016.	2.2	16
26	Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 583-589.	4.4	60
27	Case series of a hybrid closed-loop system used in pregnancies in clinical practice. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3248.	4.0	32
28	Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk. <i>Mayo Clinic Proceedings</i> , 2020, 95, 614-615.	3.0	3
29	An Intolerable Burden: Suicide, Intended Self-Injury and Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 541-544.	0.8	6
30	Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 187-193.	2.3	7
31	A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 538-540.	4.4	7
32	266-OR: Rebound Hyperglycemia in Real-World Data and Its Mitigation with a CGM-Based Predictive Alert. <i>Diabetes</i> , 2020, 69, .	0.6	0
33	Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 736-739.	4.4	11
34	Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. <i>Diabetic Medicine</i> , 2019, 36, 1075-1081.	2.3	124
35	Adverse Events Associated With Immune Checkpoint Inhibitors. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1219.	7.4	7
36	Unhealthy Cannabis Use among Recreational and Medical Cannabis Users with Type 1 Diabetes. <i>Canadian Journal of Addiction</i> , 2019, 10, 38-41.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Technological advances shaping diabetes care. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 84-89.	2.3	21
38	Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 115.	5.1	30
39	836-P: Cannabis Use in Adults with Type 1 Diabetes (T1D) Is Associated with Poor Glycemic Control and Increased Risk for Diabetic Ketoacidosis (DKA). <i>Diabetes</i> , 2019, 68, 836-P.	0.6	2
40	1066-P: Improvement in Time-in-Range (TIR) with Real-Life Use of Hybrid Closed-Loop System in Patients with Type 1 Diabetes (T1D). <i>Diabetes</i> , 2019, 68, .	0.6	0
41	1079-P: Glycemic Control and Change in Insulin Dose with Real-Life Use of Hybrid Closed-Loop System. <i>Diabetes</i> , 2019, 68, 1079-P.	0.6	0
42	1738-P: Immune Checkpoint Inhibitor Therapy Precipitates the Rapid Development of Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1738-P.	0.6	0
43	Management of Type 1 diabetes should be different from Type 2 diabetes at hospital admission. <i>Diabetic Medicine</i> , 2018, 35, 824-824.	2.3	0
44	Over-the-Counter "Adrenal Support" Supplements Contain Thyroid and Steroid-Based Adrenal Hormones. <i>Mayo Clinic Proceedings</i> , 2018, 93, 284-290.	3.0	13
45	Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018, 378, 1163-1165.	27.0	79
46	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. <i>Current Problems in Cardiology</i> , 2018, 43, 68-110.	2.4	22
47	Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 733-734.	2.2	2
48	PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3589-3592.	3.6	35
49	Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 639-647.	4.4	36
50	SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 246-250.	2.3	12
51	The cortisol stress response induced by surgery: A systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2018, 89, 554-567.	2.4	107
52	A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 391-394.	4.4	30
53	Ever-Increasing Insulin-Requiring Patients Globally. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S2-1-S2-4.	4.4	62
54	Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S2-24-S2-32.	4.4	27

#	ARTICLE	IF	CITATIONS
55	New-onset insulin-dependent diabetes due to nivolumab. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.5	14
56	Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patientsâ€™STAT Study. <i>Diabetes</i> , 2018, 67, 1017-P.	0.6	1
57	Improved Postprandial Blood Glucose (PPBG) Excursions with Technosphere Inhaled Insulin (TI) Compared with Aspart in T1D Patientsâ€™STAT Study. <i>Diabetes</i> , 2018, 67, 348-OR.	0.6	1
58	Rapidly Enlarging Thyroid Mass in a Patient With History of Multiple Cancers. <i>JAMA Oncology</i> , 2017, 3, 853.	7.1	0
59	Implications and Interpretations of Differences in Age-Adjusted Testosterone Levelsâ€™Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 744.	5.1	0
60	The Future of Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-1-S-2.	4.4	14
61	Flash Glucose Monitoring: The Future Is Here. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-1-S-3.	4.4	19
62	Alcohol Consumption, Diabetes Risk, and Cardiovascular Disease Within Diabetes. <i>Current Diabetes Reports</i> , 2017, 17, 136.	4.2	78
63	Role of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStarÂ® in Type 1 Diabetes Management. <i>Diabetes Therapy</i> , 2017, 8, 811-819.	2.5	32
64	Toxoplasma Infection in an Immunocompetent Host: Possible Risk of Living with Multiple Cats. <i>Cureus</i> , 2017, 9, e1103.	0.5	6
65	Previously unreported abnormalities in Wolfram Syndrome Type 2. <i>Pediatric Endocrinology, Diabetes and Metabolism</i> , 2017, 23, 107-110.	0.7	8
66	Diabetes mellitus and hypertension. <i>Current Opinion in Cardiology</i> , 2016, 31, 402-409.	1.8	38
67	Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase. <i>JAMA Internal Medicine</i> , 2016, 176, 1743.	5.1	2
68	Elephantiasis nostras verrucosa. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013200363-bcr2013200363.	0.5	1
69	Linagliptin for the treatment of Type 2 diabetes. <i>Diabetes Management</i> , 2014, 4, 85-101.	0.5	2
70	Are we missing anaerobic infective endocarditis in some acute coronary syndromes?. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204791-bcr2014204791.	0.5	0
71	Glargine safety, diabetes and cancer. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 247-263.	2.4	16
72	How far you can trust c-ANCA?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013008555-bcr2013008555.	0.5	1

#	ARTICLE	IF	CITATIONS
73	Platelet-Derived Growth Factor CC-Mediated Neuroprotection against HIV Tat Involves TRPC-Mediated Inactivation of GSK 3beta. PLoS ONE, 2012, 7, e47572.	2.5	28
74	Health Care Professionalsâ€™ Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes. Journal of Diabetes Science and Technology, 0, , 193229682211016.	2.2	0
75	Retained Diabetes Devicesâ€™ A Literature Review. Journal of Diabetes Science and Technology, 0, , 193229682211058.	2.2	0